A Phase II study of paclitaxel-ifosfamide-cisplatin combination in advanced nonsmall cell lung carcinoma
Open Access
- 15 August 2000
- Vol. 89 (4) , 774-782
- https://doi.org/10.1002/1097-0142(20000815)89:4<774::aid-cncr9>3.0.co;2-5
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumoursBritish Journal of Cancer, 2000
- Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.Journal of Clinical Oncology, 1998
- A phase I trial of ifosfamide and paclitaxel with granulocyte‐colony stimulating factor in the treatment of patients with refractory solid tumorsCancer, 1998
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative GroupsAnnals of Oncology, 1995
- Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)European Journal Of Cancer, 1993
- The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivoBiochemical Pharmacology, 1989
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compareBritish Journal of Cancer, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958